Dental Care Clinics in Aberdeen, NJ Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Friendly Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 112 Oxford Lane, Aberdeen, NJ 07747 Phone: 732-566-8484 Fax: 732-566-2746 |
Friendlydentalnj Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 112 Oxford Ln, Aberdeen, NJ 07747 Phone: 732-566-8484 |
Aberrdeen Family Dental Pa Dentist Medicare: Not Enrolled in Medicare Practice Location: 1077 Rte 34 Ste J, Aberdeen, NJ 07747 Phone: 732-441-3600 Fax: 732-441-3601 |
Mint Orthodontics Llc Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 911 Wellington Pl, Aberdeen, NJ 07747 Phone: 732-618-2614 Fax: 732-696-8124 |
News Archive
Registration open for 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Registration for the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) - which will take place in Kuala Lumpur, Malaysia, from June 30 to July 3, 2013 - is now open through the conference webpage, which notes "[d]elegates are encouraged to register by 18 April 2013 ... to avoid the late fee surcharge, which begins on 19 April."
Data shows drop in natural disaster-related deaths, growing economic losses; Sen. Murkowski moves to halt EPA greenhouse gas regulation
New data from the WHO and the Belgian Centre for Research on Epidemiology of Disasters Deaths and released at the U.N. climate conference show the number of people dying in climate-related disasters has decreased, and that economic losses from natural disasters are growing, Reuters AlertNet reports.
Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer
Amgen today announced the U.S. Food and Drug Administration has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
Thermo Fisher Scientific first quarter revenues increase 14% to record $3.10 billion
Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the first quarter ended March 31, 2012.
› Verified 7 days ago